Lunai Bioworks (LNAI) Non-Current Assets (2012 - 2026)
Lunai Bioworks (LNAI) posted quarterly Non-Current Assets of $6.1 million for Q1 2026, down 94.63% year-over-year from $114.1 million in Q1 2025, and little changed quarter-over-quarter from $6.2 million in Q4 2025.
Lunai Bioworks (LNAI) Non-Current Assets (2012 - 2026) Analysis & Trends
Lunai Bioworks' Non-Current Assets history runs 15 years deep, the most recent figure standing at $6.1 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 94.63% year-over-year to $6.1 million; the TTM figure through Mar 2026 stood at $25.6 million (down 94.92% YoY), while the FY2025 annual figure was $7.2 million, down 95.54% from the prior year.
- Non-Current Assets for Q1 2026 stood at $6.1 million, roughly flat from $6.2 million in the prior quarter.
- The five-year high for Non-Current Assets was $176.9 million in Q1 2024, with the low at $6.1 million in Q1 2026.
- The 5-year median for Non-Current Assets is $74.9 million (2022), against an average of $79.0 million.
- The sharpest annual moves came in 2024 and 2025: Non-Current Assets soared 189.1% in 2024, then plunged 95.54% in 2025.
- Lunai Bioworks' Non-Current Assets stood at $74.9 million in 2022, then dropped by 25.73% to $55.6 million in 2023, then surged by 97.13% to $109.6 million in 2024, then tumbled by 94.39% to $6.2 million in 2025, then decreased by 0.39% to $6.1 million in 2026.
- Business Quant data shows LNAI's Non-Current Assets at $6.1 million in Q1 2026, $6.2 million in Q4 2025, and $6.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Lunai Bioworks | 6.87 Mn | 3.72 Mn | 20,942.00 | 6.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.13 Mn |
| Dec 31, 2025 | 6.15 Mn |
| Sep 30, 2025 | 6.16 Mn |
| Jun 30, 2025 | 7.18 Mn |
| Mar 31, 2025 | 114.06 Mn |
| Dec 31, 2024 | 109.63 Mn |
| Sep 30, 2024 | 119.88 Mn |
| Jun 30, 2024 | 161.13 Mn |
| Mar 31, 2024 | 176.87 Mn |
| Dec 31, 2023 | 55.61 Mn |
| Sep 30, 2023 | 55.66 Mn |
| Jun 30, 2023 | 55.74 Mn |
| Mar 31, 2023 | 74.80 Mn |
| Dec 31, 2022 | 74.88 Mn |
| Sep 30, 2022 | 74.94 Mn |
| Jun 30, 2022 | 75.07 Mn |
| Mar 31, 2022 | 168.40 Mn |
| Dec 31, 2021 | 168.52 Mn |
| Sep 30, 2021 | 168.61 Mn |
| Jun 30, 2021 | 168.71 Mn |